Emergency Medicine · Medical Literature
FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose
Abstract
The US Food and Drug Administration (FDA) approved another over-the-counter intranasal naloxone product, marketed as Rextovy, for the emergency treatment of opioid overdose.
Clinical relevance
The FDA approval of Rextovy (naloxone hydrochloride 4 mg intranasal spray, Amphastar Pharmaceuticals) on June 16, 2026, addresses the persistent gap in bystander access to opioid overdose reversal agents, particularly in communities disproportionately burdened by illicit fentanyl. As the third OTC naloxone nasal spray now available without a prescription at pharmacies, convenience stores, and online retailers, this approval expands market supply, introduces price competition, and offers alternative sourcing—critical levers for a public health crisis in which 68,632 overdose deaths still occurred in the 12-month period ending December 2025. Emergency physicians and specialists should be aware of this agent to counsel high-risk patients and their households on carrying a readily accessible reversal option.
Key findings
1. Rextovy is a 4 mg naloxone hydrochloride nasal spray—bioequivalent in dose to Narcan (Emergent BioSolutions)—approved OTC on June 16, 2026; a third OTC product, RiVive (Harm Reduction Therapeutics), contains 3 mg. 2. Overdose deaths declined from 111,451 (12-month period ending August 2023, coinciding with the first OTC naloxone approval) to 68,632 (12-month period ending December 2025), representing an approximate 38% reduction; a 26% single-year drop was observed from 2023 to 2024 per Trust for America's Health. 3. Illicit fentanyl (~8-hour half-life) substantially outlasts intranasal naloxone (half-life approximately 60–120 minutes; time to peak plasma concentration 15–30 minutes; nasal bioavailability ~50%), creating a pharmacokinetic mismatch and clinically significant risk of re-narcotization after apparent recovery. 4. Rextovy packaging mandates a five-step pictorial protocol, including an explicit instruction to call 911 after the first dose; a second dose in the contralateral nostril is indicated if no response occurs within 2–3 minutes. 5. The product is FDA-labeled as safe to administer even when opioid involvement is uncertain, supporting empiric use by untrained bystanders. 6. No randomized controlled trial data or NNT/NNH values are reported in the available abstract; the clinical evidence base is derived from regulatory bioequivalence standards and epidemiological overdose mortality trends. NOTE: Quantitative efficacy data specific to Rextovy are not available from the published abstract; figures cited are drawn from FDA press release data referenced in the JAMA report.
Practice implications
Emergency clinicians should routinely co-prescribe or recommend OTC naloxone (Rextovy, Narcan, or RiVive) to all patients presenting with opioid use disorder, chronic opioid therapy, or witnessed overdose, emphasizing that Rextovy requires no prescription and is available at pharmacies and online. Given the pharmacokinetic mismatch between naloxone and illicit fentanyl, patients and bystanders must be explicitly counseled that symptom resolution after a single dose does not indicate safety—EMS activation (911) is mandatory after every administration, and re-narcotization may occur within 60–120 minutes. Expanding institutional and community distribution programs to stock Rextovy alongside existing OTC agents may reduce cost barriers and supply chain vulnerability, particularly in high-burden states such as West Virginia, Kentucky, Ohio, and Pennsylvania.